Health Science Center to Launch Antibiotic Models for Improved Patient Care; Future Deployment of Wide Range of Models Approved for…
HOUSTON, TX / ACCESSWIRE / December 6, 2023 / Every form of cancer is devastating, but the unfortunate reality is…
HOUSTON, TX / ACCESSWIRE / December 6, 2023 / Every form of cancer is devastating, but the unfortunate reality is…
Upcoming PDUFA goal date of January 3, 2024 U.S. patent protection for cosibelimab through at least May 2038 WALTHAM, Mass.,…
VIENNA, Va.--(BUSINESS WIRE)--$CVM #Multikine--CEL-SCI Corporation (NYSE American: CVM) today announced that the British National Institute for Health and Care Excellence…
VIENNA, Va.--(BUSINESS WIRE)--$CVM #Multikine--CEL-SCI Corporation (NYSE American: CVM) today announced that the British National Institute for Health and Care Excellence…
INB03 increases uptake of deruxtecan, the immunotoxin associated with trastuzumab deruxtecan (T-DXd, ENHERTU®), in models of resistant MUC4 expressing HER2 positive breast…
First subject has been dosed in the first-in-man Phase 1 clinical study of SAB-142, the first fully-human anti-thymocyte immunoglobulin (ATG)…
Four cancer types now included in PeptiCRAd-1 with Pembrolizumab trial: sarcoma, melanoma, triple negative breast cancer and non-small cell lung…
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (Nasdaq:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology…